Ernexa Therapeutics (ERNAW) Other Non Operating Income (2017 - 2025)
Ernexa Therapeutics (ERNAW) reported Other Non Operating Income of -$519000.0 for Q4 2025, down 102.31% on a YoY basis from $22.5 million in Q4 2024, and down 8550.0% quarter-over-quarter from -$6000.0 in Q3 2025.
Ernexa Therapeutics (ERNAW) Other Non Operating Income (2017 - 2025) Analysis & Trends
Ernexa Therapeutics has reported Other Non Operating Income for 9 years, with the latest figure at -$519000.0 in Q4 2025.
- For the quarter ending Q4 2025, Other Non Operating Income fell 102.31% year-over-year to -$519000.0; the trailing twelve-month figure through Dec 2025 stood at -$783000.0 (down 4993.75% YoY), and the FY2025 full-year result was $215000.0, up 207.14% from the prior year.
- Other Non Operating Income for Q4 2025 stood at -$519000.0, down from -$6000.0 in the prior quarter.
- The five-year high for Other Non Operating Income was $22.5 million in Q4 2024, with the low at -$22.4 million in Q3 2024.
- Historically, Other Non Operating Income has averaged -$71555.6 across 5 years, with a median of -$12000.0 in 2022.
- The largest YoY upside for Other Non Operating Income was 42571.7% in 2024 against a maximum downside of 2243900.0% in 2024.
- Ernexa Therapeutics' Other Non Operating Income stood at $634000.0 in 2021, then slumped by 96.06% to $25000.0 in 2022, then slumped by 312.0% to -$53000.0 in 2023, then surged by 42571.7% to $22.5 million in 2024, then slumped by 102.31% to -$519000.0 in 2025.
- The last three Other Non Operating Income figures came in at -$519000.0 (Q4 2025), -$6000.0 (Q3 2025), and -$123000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ernexa Therapeutics | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -519,000.00 |
| Sep 30, 2025 | -6,000.00 |
| Jun 30, 2025 | -123,000.00 |
| Mar 31, 2025 | -135,000.00 |
| Dec 31, 2024 | 22.51 Mn |
| Sep 30, 2024 | -22.44 Mn |
| Dec 31, 2023 | -53,000.00 |
| Sep 30, 2023 | -1,000.00 |
| Jun 30, 2023 | -280,000.00 |
| Mar 31, 2023 | 1,000.00 |
| Dec 31, 2022 | 25,000.00 |
| Sep 30, 2022 | -10,000.00 |
| Jun 30, 2022 | -14,000.00 |
| Mar 31, 2022 | -1.14 Mn |
| Dec 31, 2021 | 634,000.00 |
| Sep 30, 2021 | 290,000.00 |
| Jun 30, 2021 | -22,000.00 |
| Mar 31, 2021 | -3,000.00 |
| Dec 31, 2020 | -11,518.00 |
| Sep 30, 2020 | -12,559.00 |